IL149404A0 - METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION - Google Patents

METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION

Info

Publication number
IL149404A0
IL149404A0 IL14940402A IL14940402A IL149404A0 IL 149404 A0 IL149404 A0 IL 149404A0 IL 14940402 A IL14940402 A IL 14940402A IL 14940402 A IL14940402 A IL 14940402A IL 149404 A0 IL149404 A0 IL 149404A0
Authority
IL
Israel
Prior art keywords
catenin
phosphorylation
compositions
beta
modulators
Prior art date
Application number
IL14940402A
Other languages
English (en)
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Priority to IL14940402A priority Critical patent/IL149404A0/xx
Publication of IL149404A0 publication Critical patent/IL149404A0/xx
Priority to ES03717515T priority patent/ES2349498T3/es
Priority to DE60333460T priority patent/DE60333460D1/de
Priority to AU2003222426A priority patent/AU2003222426A1/en
Priority to PT03717515T priority patent/PT1528928E/pt
Priority to AT03717515T priority patent/ATE474588T1/de
Priority to EP03717515A priority patent/EP1528928B1/de
Priority to PCT/IL2003/000340 priority patent/WO2003092719A2/en
Priority to US10/972,921 priority patent/US20050171005A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01048—Histone acetyltransferase (2.3.1.48)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03016—Phosphoprotein phosphatase (3.1.3.16), i.e. calcineurin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IL14940402A 2002-04-29 2002-04-29 METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION IL149404A0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IL14940402A IL149404A0 (en) 2002-04-29 2002-04-29 METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION
ES03717515T ES2349498T3 (es) 2002-04-29 2003-04-28 Métodos y composiciones para modular la fosforilación de la beta-catenina.
DE60333460T DE60333460D1 (de) 2002-04-29 2003-04-28 Methoden und zusammensetzungen zur beeinflussung d
AU2003222426A AU2003222426A1 (en) 2002-04-29 2003-04-28 Methods and compositions for modulating beta-catenin phosphorylation
PT03717515T PT1528928E (pt) 2002-04-29 2003-04-28 Métodos e composições para modular a fosforilação de betacatenina
AT03717515T ATE474588T1 (de) 2002-04-29 2003-04-28 Methoden und zusammensetzungen zur beeinflussung der phosphorylierung des beta-catenins
EP03717515A EP1528928B1 (de) 2002-04-29 2003-04-28 Methoden und zusammensetzungen zur beeinflussung der phosphorylierung des beta-catenins
PCT/IL2003/000340 WO2003092719A2 (en) 2002-04-29 2003-04-28 Methods and compositions for modulating beta-catenin phosphorylation
US10/972,921 US20050171005A1 (en) 2002-04-29 2004-10-25 Methods and compositions for modulating beta-catenin phosphorylation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL14940402A IL149404A0 (en) 2002-04-29 2002-04-29 METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION

Publications (1)

Publication Number Publication Date
IL149404A0 true IL149404A0 (en) 2002-11-10

Family

ID=28460385

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14940402A IL149404A0 (en) 2002-04-29 2002-04-29 METHODS AND COMPOSITIONS FOR MODULATING β-CATENIN PHOSPHORYLATION

Country Status (8)

Country Link
EP (1) EP1528928B1 (de)
AT (1) ATE474588T1 (de)
AU (1) AU2003222426A1 (de)
DE (1) DE60333460D1 (de)
ES (1) ES2349498T3 (de)
IL (1) IL149404A0 (de)
PT (1) PT1528928E (de)
WO (1) WO2003092719A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007092414A2 (en) * 2006-02-06 2007-08-16 Lixte Biotechnology Holdings, Inc. Use of phosphatases to treat tumors overexpressing n-cor
CA2909160C (en) 2013-04-09 2021-05-25 Lixte Biotechnology, Inc. Formulations of oxabicycloheptanes and oxabicycloheptenes
EP3283642B1 (de) * 2015-04-17 2023-10-11 Netherlands Translational Research Center Holding B.V. Prognostische biomarker für die ttk-inhibitor-chemotherapie
WO2018107004A1 (en) 2016-12-08 2018-06-14 Lixte Biotechnology, Inc. Oxabicycloheptanes for modulation of immune response
KR102264305B1 (ko) * 2019-07-23 2021-06-14 한국생명공학연구원 인산화된 베타-카테닌에 특이적으로 결합하는 항체 및 이의 용도
CN117045802A (zh) * 2023-07-21 2023-11-14 中国人民解放军海军军医大学 蛋白磷酸酶pp2a抑制剂与吉西他滨联合在制备抗肿瘤药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0551200A1 (de) * 1992-01-07 1993-07-14 National University Of Singapore Protein-Phosphatase-Inhibitoren zur Verwendung in der Therapie
KR950702994A (ko) * 1992-08-12 1995-08-23 로렌스 티. 웰츠 탁솔과 복합된, 단백질 키나제 억제제 및 관련 화합물(protein kinase inhibitors and related compounds combined with taxol)
US5516631A (en) * 1992-10-13 1996-05-14 La Jolla Cancer Research Foundation Method of inhibiting replication of hyperproliferative cells
US6562589B1 (en) * 1997-06-17 2003-05-13 The United States Of America As Represented By The Department Of Health And Human Services AIB1, a novel steroid receptor co-activator
WO1999004238A2 (en) * 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders
DE19747418C1 (de) * 1997-10-27 1999-07-15 Deutsches Krebsforsch Inhibitor-Protein des wnt-Signalwegs
US6512102B1 (en) * 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
AU1700700A (en) * 1999-11-05 2001-05-14 Forskarpatent I Syd Ab Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
EP1170008A1 (de) * 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproinsäure und dessen Derivate als Inhibitoren der Histone deacetylase
WO2002024941A2 (en) * 2000-09-22 2002-03-28 University Of Dundee Protein kinase regulation

Also Published As

Publication number Publication date
DE60333460D1 (de) 2010-09-02
ES2349498T3 (es) 2011-01-04
ATE474588T1 (de) 2010-08-15
EP1528928A2 (de) 2005-05-11
EP1528928B1 (de) 2010-07-21
PT1528928E (pt) 2010-10-26
WO2003092719A3 (en) 2004-03-18
WO2003092719A2 (en) 2003-11-13
AU2003222426A1 (en) 2003-11-17

Similar Documents

Publication Publication Date Title
ATE203545T1 (de) Substrate und inhibitoren von proteolytischen enzymen
UY27362A1 (es) Métodos de usar inhibidores de epóxido hidrolasa soluble
DK1592786T3 (da) Diagnosticering og behandling af multipel sulfatase-defekt og andet ved anvendelse af et formylglycin-dannende enzym (FGE).
CY1109006T1 (el) Παραγωγα πουρινης ως αναστολεις κινασης
BRPI0414599A (pt) pirrol-indóis substituìdos
TW200519089A (en) Biaryl sulfonamides and methods for using same
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
TW200519100A (en) Biaryl sulfonamides and methods for using same
WO2003076899A3 (en) Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents
MY144672A (en) Inhibitors of cytosolic phospholipase a2
GEP20074215B (en) Novel method for the industrial synthesis of strontium ranelate and the hydrates thereof
DE602005023068D1 (de) Verfahren und system zur zuweisung von kommunikationsressourcen
AU2003290592A1 (en) Antitumor benzoylsulfonamides
AU2003222426A1 (en) Methods and compositions for modulating beta-catenin phosphorylation
ATE507209T1 (de) Referenzstandard zur charakterisierung von rosuvastatin
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
DK1506313T3 (da) Fremgangsmåder til screening af modulatorer af den mitokondrielle NAD-afhængige deacetylase SIRT3
MXPA04004018A (es) Metodos de separacion por exclusion para toxicidad de compuestos de prueba.
UY28653A1 (es) N-alquil pirroles como inhibidores de la hmg-coa reductasa
TW200510276A (en) Calcilytic compounds
AR027327A1 (es) Procedimiento para la separacion einzimatica de racematos de derivados de aminometil-aril-ciclohezanol
ATE351906T1 (de) Zur modulation der krebszellenproliferation geeignetes polynukleotid
FI20031191A7 (fi) Monoamiinin takaisinoton estäjä
DE60320844D1 (de) Kristallstruktur der glutamatracemase (muri)
WO2003103709A3 (en) Cd200-receptor mediated modulation of bone development